CytomX Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.41 Insider Own0.70% Shs Outstand65.39M Perf Week-2.14%
Market Cap117.80M Forward P/E- EPS next Y-1.31 Insider Trans0.00% Shs Float64.54M Perf Month13.66%
Income-91.90M PEG- EPS next Q-0.37 Inst Own85.60% Short Float5.92% Perf Quarter-33.94%
Sales70.70M P/S1.67 EPS this Y-82.90% Inst Trans-1.13% Short Ratio3.44 Perf Half Y-59.06%
Book/sh1.04 P/B1.76 EPS next Y16.30% ROA-26.10% Target Price10.88 Perf Year-71.09%
Cash/sh4.08 P/C0.45 EPS next 5Y-0.90% ROE-91.90% 52W Range1.50 - 7.53 Perf YTD-57.74%
Dividend- P/FCF- EPS past 5Y4.30% ROI-93.70% 52W High-75.23% Beta0.60
Dividend %- Quick Ratio2.60 Sales past 5Y35.80% Gross Margin- 52W Low23.92% ATR0.14
Employees174 Current Ratio2.60 Sales Q/Q6.90% Oper. Margin- RSI (14)53.48 Volatility7.49% 7.99%
OptionableYes Debt/Eq0.00 EPS Q/Q-43.20% Profit Margin- Rel Volume0.37 Prev Close1.83
ShortableYes LT Debt/Eq0.00 EarningsMay 05 AMC Payout- Avg Volume1.11M Price1.87
Recom1.70 SMA203.81% SMA506.18% SMA200-53.03% Volume352,114 Change1.91%
Jun-24-22Initiated BMO Capital Markets Outperform $9
Jan-18-22Upgrade Barclays Underweight → Overweight $7
Nov-15-21Initiated BTIG Research Buy $16
May-28-21Downgrade Barclays Equal Weight → Underweight $9 → $7
Mar-29-21Initiated JP Morgan Overweight $14
Mar-23-21Upgrade Jefferies Hold → Buy
Sep-22-20Downgrade Guggenheim Buy → Neutral
Jun-01-20Downgrade Jefferies Buy → Hold $16 → $10
May-14-20Reiterated H.C. Wainwright Buy $16 → $12
Mar-24-20Upgrade Wedbush Neutral → Outperform
Mar-04-20Initiated Barclays Equal Weight $7
Nov-20-19Initiated Guggenheim Buy
Nov-11-19Downgrade Wedbush Outperform → Neutral $25 → $8
Jun-13-19Initiated Mizuho Buy
May-14-19Initiated Cantor Fitzgerald Overweight $21
Mar-11-19Initiated Barclays Overweight $16
Nov-26-18Initiated Piper Jaffray Overweight $22
Oct-15-18Initiated Goldman Neutral $21
Sep-13-18Initiated H.C. Wainwright Buy $32
Jun-01-18Initiated SunTrust Buy $38
Jun-27-22 08:33AM  
Jun-16-22 08:00AM  
Jun-01-22 08:00AM  
May-26-22 08:00AM  
May-07-22 08:11AM  
May-06-22 10:30PM  
May-05-22 06:25PM  
Apr-28-22 08:00AM  
Apr-14-22 04:15PM  
Apr-06-22 06:47AM  
Mar-23-22 04:15PM  
Mar-17-22 08:00AM  
Mar-02-22 01:00AM  
Mar-01-22 05:45PM  
Feb-28-22 05:15PM  
Feb-22-22 08:00AM  
Feb-16-22 08:00AM  
Feb-07-22 09:00AM  
Feb-05-22 08:05AM  
Jan-26-22 08:15AM  
Jan-20-22 10:41AM  
Jan-19-22 08:00AM  
Jan-10-22 08:21AM  
Jan-05-22 08:00AM  
Dec-27-21 06:56AM  
Dec-21-21 12:12PM  
Dec-20-21 04:05PM  
Nov-17-21 10:01AM  
Nov-11-21 08:00AM  
Nov-07-21 07:31AM  
Nov-05-21 07:30AM  
Nov-04-21 06:05PM  
Nov-01-21 08:00AM  
Oct-28-21 03:05PM  
Oct-18-21 08:00AM  
Oct-04-21 08:00AM  
Sep-16-21 08:00AM  
Sep-07-21 08:00AM  
Aug-17-21 08:00AM  
Aug-09-21 02:40AM  
Aug-07-21 11:30AM  
Aug-05-21 05:35PM  
Aug-04-21 08:00AM  
Aug-02-21 08:00AM  
Jul-29-21 03:04PM  
Jul-14-21 10:00AM  
Jun-21-21 08:00AM  
Jun-10-21 01:17AM  
May-27-21 08:00AM  
May-21-21 03:01AM  
May-08-21 01:30PM  
May-06-21 06:05PM  
Apr-29-21 08:00AM  
Apr-14-21 04:01PM  
Mar-24-21 08:00AM  
Mar-02-21 12:00PM  
Feb-25-21 09:01AM  
Feb-24-21 04:15PM  
Feb-23-21 10:25AM  
Feb-22-21 08:00AM  
Feb-20-21 02:44AM  
Feb-19-21 08:00AM  
Feb-17-21 08:00AM  
Feb-04-21 08:00AM  
Feb-03-21 08:19AM  
Jan-26-21 08:00AM  
Jan-20-21 09:50PM  
Jan-19-21 04:35PM  
Jan-07-21 08:00AM  
Dec-24-20 10:10AM  
Dec-22-20 04:05PM  
Dec-03-20 08:00AM  
Nov-11-20 04:01PM  
Nov-07-20 08:40AM  
Nov-06-20 03:01PM  
Nov-05-20 08:00PM  
Oct-29-20 12:34PM  
Oct-09-20 08:32AM  
Oct-06-20 05:41PM  
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McCarthy Sean A.President and CEOMay 09Option Exercise0.9490,93185,930265,853May 11 04:51 PM
McCarthy Sean A.President and CEOAug 11Option Exercise1.1392,113104,44799,922Aug 13 05:22 PM